IXICO (LON:IXI) Full Year 2024 Results
Key Financial Results
- Revenue: UK£5.77m (down 14% from FY 2023).
- Net loss: UK£2.00m (loss widened by 70% from FY 2023).
- UK£0.041 loss per share (further deteriorated from UK£0.024 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
IXICO Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) also surpassed analyst estimates by 10.0%.
The company's shares are down 12% from a week ago.
Risk Analysis
You should learn about the 5 warning signs we've spotted with IXICO (including 2 which are significant).
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:IXI
IXICO
Provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, the Netherlands, Ireland, rest of Europe, and the United States.
Flawless balance sheet moderate.
